Furthermore, studies have shown that programmed cell death ligand 1 (PDL1) on sEVs is a pool that directly interacts with programmed cell death 1 on cells to promote tumor growth [45] and mediate immune evasion in GBM [46], which affects the outcome of immunotherapy. This evidence concerns the gene CD274 and glioblastoma.